Related Experiment Video

Updated: Mar 31, 2026

The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice
09:03

The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice

Published on: February 3, 2012

20.0K

For patients with rheumatic disease and hepatitis C infection: the end of interferon

Leonard H Calabrese1, Patrice P Cacoub2

  • 1Cleveland Clinic Lerner, College of Medicine of Case Western Reserve University, RJ Fasenmyer Chair of Clinical Immunology, Cleveland Clinic, Cleveland, Ohio , USA.

RMD Open
|October 29, 2015
PubMed

Insights

Hepatitis C virus (HCV) treatment is advancing with interferon-free therapies, offering better tolerability and effectiveness. Early screening for HCV is crucial for patients with rheumatic diseases to ensure optimal, safe management.

Area of Science:

  • Hepatology and Rheumatology
  • Viral Gastroenterology
  • Immunology

Background:

  • Hepatitis C virus (HCV) presents rare rheumatic complications and is a common comorbidity in rheumatic diseases.
  • Traditional interferon-based HCV treatments are poorly tolerated and associated with autoimmune toxicities, complicating management for rheumatic patients.
  • Emerging direct-acting antiviral (DAA) regimens offer effective, interferon-free treatment options.

Purpose of the Study:

  • To highlight the significance of interferon-free treatment advancements for Hepatitis C virus (HCV).
  • To emphasize the increased importance of HCV screening in patients with rheumatic diseases.
  • To inform rheumatologists about new therapeutic strategies and the need for collaborative care with hepatologists.

Main Methods:

  • Review of current and emerging Hepatitis C virus (HCV) treatment modalities.
  • Analysis of the impact of traditional interferon-based therapies on patients with rheumatic diseases.
  • Discussion of the benefits and implications of direct-acting antiviral (DAA) regimens.

Main Results:

  • Interferon-free regimens demonstrate superior efficacy and tolerability compared to older treatments.
  • DAAs eliminate the need for interferon, reducing risks of autoimmune toxicities in rheumatic patients.
  • The advent of effective interferon-free therapies underscores the critical need for proactive HCV screening.

Conclusions:

  • Interferon-free treatments represent a paradigm shift in Hepatitis C virus (HCV) management.
  • Enhanced knowledge of these advances is essential for rheumatologists to optimize patient care.
  • Collaborative management between rheumatologists and hepatologists is key to achieving effective and safe HCV treatment outcomes.

Keywords:
AutoimmunityInfectionsTreatment

More Related Videos

Zika Virus Infectious Cell Culture System and the In Vitro Prophylactic Effect of Interferons09:11

Zika Virus Infectious Cell Culture System and the In Vitro Prophylactic Effect of Interferons

Published on: August 23, 2016

21.6K
A Protocol for Analyzing Hepatitis C Virus Replication13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

24.8K

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
37
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
24
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
493
Cytomegalovirus Disease01:27

Cytomegalovirus Disease

Cytomegalovirus (CMV) disease is caused by human cytomegalovirus, a double-stranded DNA virus of the Herpesviridae family. While primary CMV infection is often asymptomatic in immunocompetent individuals, the virus can cause severe disease in neonates and immunocompromised patients. CMV is the most common cause of congenital viral infection in the United States, and a major pathogen in solid organ and hematopoietic stem cell transplant recipients.CMV is transmitted via bodily fluids, sexual...
24
Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
856
Rheumatic Heart Disease IV: Nursing Management01:20

Rheumatic Heart Disease IV: Nursing Management

AssessmentA comprehensive assessment is essential in managing a patient with rheumatic heart disease (RHD). Begin with obtaining a detailed medical history, including recent streptococcal infections, a history of rheumatic fever, or previously diagnosed rheumatic heart disease. Assess the patient for symptoms such as fever, chest pain, widespread joint pain (arthralgia), tachycardia, pericardial friction rub, muffled heart sounds, heart murmurs, peripheral edema, subcutaneous nodules, and...
452